+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Amyloid beta40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice



Amyloid beta40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice



Journal of Alzheimer's Disease 3(1): 23-30



An important event in the pathogenesis of Alzheimer's disease (AD) is the deposition of the amyloid beta (Abeta)1-40 and 1-42 peptides in a fibrillar form, with Abeta42 typically having a greater propensity to undergo this conformational change. A major risk factor for late-onset AD is the inheritance of the apolipoprotein E (apoE) 4 allele [3,14,31]. We previously proposed that apoE may function as a "pathological chaperone" in the pathogenesis of AD (i.e. modulate the structure of Abeta, promoting or stabilizing a beta-sheet conformation), prior to the discovery of this linkage [7,40,41,42]. Data from apoE knockout / AbetaPP^(V717F) mice, has shown that the presence of apoE is necessary for cerebral amyloid formation [1,2], consistent with our hypothesis. However, in betaPP^(V717F) mice expressing human apoE3 or E4 early Abeta deposition at 9 months is suppressed, but by 15 months both human apoE expressing mice had significant fibrillar Abeta deposits with the apoE4 expressing mice having a 10 fold greater amyloid burden [8,9]. This and other data has suggested that apoE, in addition to having a facilitating role in fibril formation, may also influence clearance of Abeta peptides. In order to address if apoE affects the clearance of Abeta peptides across the blood-brain barrier (BBB) and whether there are differences in the clearance of Abeta40 versus Abeta42, we performed stereotactic, intra-ventricular micro-injections of Abeta40, Abeta42 or control peptides in wild-type, apoE knock-out (KO) or human apoE3 or apoE4 expressing transgenic mice. We found that consistent with other studies [5], Abeta40 is rapidly cleared from the brain across the BBB; however, Abeta42 is cleared much less effectively. This clearance of exogenous Abeta peptides across the BBB does not appear to be affected by apoE expression. This data suggests that Abeta42 production may favor amyloid deposition due to a reduced clearance across the BBB, compared to Abeta40. In addition, our experiments support a role of apoE as a pathological chaperone, and do not suggest an isotype specific role of apoE in exogenous Abeta peptide clearance from the CSF across the BBB.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 045217276

Download citation: RISBibTeXText

PMID: 12214069


Related references

Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation. Journal of Pharmacology and Experimental Therapeutics 313(3): 1370-1378, 2005

APOE genotype results in differential effects on the peripheral clearance of amyloid-beta42 in APOE knock-in and knock-out mice. Journal of Alzheimer's Disease 21(2): 403-409, 2010

The Psen1-L166P-knock-in mutation leads to amyloid deposition in human wild-type amyloid precursor protein YAC transgenic mice. Faseb Journal 26(7): 2899-2910, 2012

Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor protein. Biochemical and Biophysical Research Communications 386(2): 284-288, 2009

Amyloid-β contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy. Stroke 43(2): 514-523, 2012

A multifaceted role for apoE in the clearance of beta-amyloid across the blood-brain barrier. Neuro-Degenerative Diseases 11(1): 13-21, 2013

Traumatic brain injury induces amyloid beta immunoreactive deposits in the brain of transgenic mice expressing mutated human amyloid precursor protein Histological analysis of these mice and of mice coexpressing hAPP-695 and human presenilin 1. Society for Neuroscience Abstracts 23(1-2): 825, 1997

Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from human ApoE3 and ApoE4 knock-in mice. Journal of Biological Chemistry 277(33): 29919-29926, 2002

LRP - 1 binds free Abeta and promotes its clearance across the blood - brain barrier in wild - type and TIE - 2 LRP - 1 Tg mice. Society for Neuroscience Abstract Viewer & Itinerary Planner : Abstract No 667 5, 2003

Unique lipoproteins secreted by primary astrocytes from wild type, apoE (-/-), and human apoE transgenic mice. Journal of Biological Chemistry 274(42): 30001-7, 1999

Lipoprotein secretion by primary astrocytes from wild type, apoE null and human apoE transgenic mice. Society for Neuroscience Abstracts 24(1-2): 1712, 1998

Abeta40 and Abeta42 clearance in a transgenic mouse model expressing human apoE3 and apoE4. Society for Neuroscience Abstracts 25(1-2): 1058, 1999

Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg2576 mice. Journal of Neuroscience Methods 138(1-2): 233-242, 2004

Oleocanthal enhances amyloid-β clearance from the brains of TgSwDI mice and in vitro across a human blood-brain barrier model. Acs Chemical Neuroscience 6(11): 1849-1859, 2016

Intra- and extracellular amyloid fibrils are formed in cultured pancreatic islets of transgenic mice expressing human islet amyloid polypeptide. Proceedings of the National Academy of Sciences of the United States of America 91(18): 8467-8471, 1994